Overcoming Deadly Diseases

Phase 3 ACTION Study of ONC201 (dordaviprone) Now Enrolling

Improving and Extending Lives

Chimerix’s mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases.  Learn more about our approach to investing in novel drug candidates that meaningfully improve the probability of survival and the collaborative team driving the development of these promising new therapies.


Chimerix Announces the initiation of the ACTION study for patients with the H3K27M mutation.

More about ACTION

On the road with Chimerix: EANO Annual Meeting 2023

Come visit us at 18th Meeting of the European Association of Neuro-Oncology (EANO2023) in Rotterdam, Netherlands, September 21-24, 2023. Our team will be onsite to discuss ONC201, the Phase 3 ACTION study, and how using molecular profiling to identify patients most likely to benefit from therapy is driving advances in the treatment of glioma.

On Saturday, September 23rd at 1:00 pm, please join us in room Grote Zaal for our industry-sponsored session, “H3 K27M-mutant Diffuse Glioma: Diagnosis to Treatment and Future Directions,” a one-hour symposium on the diagnosis and treatment of H3 K27M-mutant diffuse glioma, with speakers Dr. Peiter Wesseling (University Medical Center, Amsterdam, NL), Dr. Susan Short (University of Leeds, Leeds, UK), and Dr. Martin van den Bent (Erasmus Medical Center, Rotterdam, NL).

Learn More


view all